^
    ER mutation
    Estrogen Receptor Positive Breast Cancer
    bevacizumab + paclitaxel
    Sensitive
    :
    C3
    ESMO-BC 2021 - 4d
    ER positive
    Estrogen Receptor Positive Breast Cancer
    tamoxifen + TAK-228
    Sensitive
    :
    C2
    Breast Cancer Res Treat - 3wk
    PTEN mutation
    Estrogen Receptor Positive Breast Cancer
    AZD5363
    Sensitive
    :
    C3
    NPJ Breast Cancer - 3wk
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HR positive
    Hormone Receptor Positive Breast Cancer
    ribociclib
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    lapatinib
    Sensitive
    :
    A1
    ER positive
    Estrogen Receptor Positive Breast Cancer
    fulvestrant
    Sensitive
    :
    A1
    HER-2 overexpression
    Hormone Receptor Positive Breast Cancer
    neratinib
    Sensitive
    :
    A1
    HR positive
    Hormone Receptor Positive Breast Cancer
    olaparib
    Sensitive
    :
    A1
    HER-2 amplification
    Hormone Receptor Positive Breast Cancer
    neratinib
    Sensitive
    :
    A1
    ER positive
    Estrogen Receptor Positive Breast Cancer
    exemestane
    Sensitive
    :
    A1
    HR positive
    Hormone Receptor Positive Breast Cancer
    letrozole
    Sensitive
    :
    A1
    HR positive
    Hormone Receptor Positive Breast Cancer
    anastrozole
    Sensitive
    :
    A1
    ER positive
    Estrogen Receptor Positive Breast Cancer
    toremifene
    Sensitive
    :
    A1
    HR positive
    Hormone Receptor Positive Breast Cancer
    talazoparib
    Sensitive
    :
    A1
    HR positive
    Hormone Receptor Positive Breast Cancer
    fulvestrant
    Sensitive
    :
    A1
    HR positive
    Hormone Receptor Positive Breast Cancer
    palbociclib
    Resistant
    :
    A2
    HR positive
    Hormone Receptor Positive Breast Cancer
    everolimus
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES